Kathryn M. McNeil
Nessuna posizione attualmente
Profilo
Kathryn M.
McNeil is former Head-Communication & Investor Relations at Invitae Corp., former VP-Investor Relations & Corporate Communications at Cellectar Biosciences, Inc. and former VP-Investor Relations & Public Relations at Novelos Therapeutics, Inc. (a subsidiary of Cellectar Biosciences, Inc.) and former Head-Investor Relations at Chelsea Therapeutics International Ltd.
She received an undergraduate degree from Wesleyan University.
Precedenti posizioni note di Kathryn M. McNeil
Società | Posizione | Fine |
---|---|---|
INVITAE CORPORATION | Public Communications Contact | 01/04/2018 |
CELLECTAR BIOSCIENCES, INC. | Investor Relations Contact | 28/07/2015 |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Investor Relations Contact | 12/02/2014 |
CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Investor Relations Contact | - |
Formazione di Kathryn M. McNeil
Wesleyan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
INVITAE CORPORATION | Health Services |
CELLECTAR BIOSCIENCES, INC. | Health Technology |
Aziende private | 2 |
---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |